2023
Multi-omic analysis reveals metabolic pathways that characterize right-sided colon cancer liver metastasis
Morris M, Jain A, Sun B, Kurbatov V, Muca E, Zeng Z, Jin Y, Roper J, Lu J, Paty P, Johnson C, Khan S. Multi-omic analysis reveals metabolic pathways that characterize right-sided colon cancer liver metastasis. Cancer Letters 2023, 574: 216384. PMID: 37716465, PMCID: PMC10620771, DOI: 10.1016/j.canlet.2023.216384.Peer-Reviewed Original ResearchConceptsLiver metastasesColon cancer liver metastasisCancer liver metastasesSided colon cancerSubset of patientsGrowth factor betaMulti-omics analysisFatty acid oxidationMetastatic diseaseInferior survivalClinical differencesClinical behaviorUntargeted metabolomics analysisTumor behaviorColon cancerBile acidsTumor cell metabolismFactor betaPatientsMetastasisPI3K-AktReactive oxygen speciesMEK-ERKLiquid chromatography-mass spectrometryRCC
2020
Liver-first approach to stage IV colon cancer with synchronous isolated liver metastases
Kurbatov V, Resio BJ, Cama CA, Heller DR, Cha C, Zhang Y, Lu J, Khan SA. Liver-first approach to stage IV colon cancer with synchronous isolated liver metastases. Journal Of Gastrointestinal Oncology 2020, 11: 76-83. PMID: 32175108, PMCID: PMC7052756, DOI: 10.21037/jgo.2020.01.03.Peer-Reviewed Original ResearchLiver-first approachIsolated liver metastasesColon adenocarcinomaLiver metastasesMultivariable Cox proportional hazards analysisCox proportional hazards analysisNational Cancer DatabaseProportional hazards analysisRisk of deathCompletion resectionResection sequenceUpfront chemotherapyExtrahepatic metastasesMedian survivalClinical outcomesHepatic metastasesCAC patientsKaplan-MeierMetastatic tumorsCancer DatabaseColon cancerCAC casesPatientsMetastasisGreater likelihood
2009
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer
Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, Libutti SK, Nakakura EK, Golub TR, Hanahan D. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes & Development 2009, 23: 2152-2165. PMID: 19759263, PMCID: PMC2751988, DOI: 10.1101/gad.1820109.Peer-Reviewed Original ResearchConceptsPrimary tumorMouse modelHallmark capabilitiesPancreatic neuroendocrine tumorsAnti-angiogenic therapyTranscription factor ZEB1MiR changesMiR-200 familyMetastatic tumorsNeuroendocrine tumorsRare subsetEnhanced metastasisAngiogenesis inhibitorsMetastasisTumorsMiR signatureNeoplastic progressionHuman tumorsAltered expressionAdaptive resistanceExpression signaturesE-cadherinCancerMiRTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply